Extensively drug-resistant tuberculosis found in CaliforniaAugust 14, 2008In the first statewide study of extensively drug-resistant tuberculosis (XDR TB) in the United States, California officials have identified 18 cases of the dangerous and difficult-to-treat disease between 1993 and 2006, and 77 cases that were one step away from XDR TB. The study appears in the August 15 issue of Clinical Infectious Diseases, now available online. California reports almost 3,000 cases of tuberculosis annually, the largest number of TB cases of any U.S. state. California has also led the nation since 2002 in the number of multidrug-resistant tuberculosis (MDR TB) cases-those that are resistant to isoniazid and rifampin, the two antibiotics that form the backbone of TB treatment. XDR TB is resistant to even more classes of antibiotics, including fluoroquinolones and one of three injectable second-line drugs. The authors of the new study evaluated drug susceptibility data of MDR TB cases identified by the California TB Registry between 1993 and 2006, looking for cases that fit the XDR TB definition. Of the 424 MDR TB cases, 4 percent were XDR and 18 percent were pre-XDR, which are one drug away from XDR TB. The proportion of patients with pre-XDR isolates increased from 7 percent in 1993 to 32 percent in 2005. XDR TB occurred due to inadequate treatment of MDR TB, XDR TB transmission within California, and infection of persons with XDR strains prior to U.S. arrival.
Over the course of the study, TB outcomes improved. Deaths declined among XDR TB cases identified after 2000. However, the authors wrote, strategies must be implemented to identify and cure MDR and pre-XDR TB cases before they develop into XDR TB. Modeling studies suggest that unless evolution of MDR into XDR is slowed, XDR cases could increase exponentially. Prevention is more cost-effective than treatment, they noted. "Globally, XDR TB has resulted from a combination of poor TB control practices, poor adherence to medications, inappropriate use of second-line drugs, lack of laboratory capacity to culture TB or assess drug susceptibility, and high HIV prevalence," said lead author Ritu Banerjee, MD, PhD of the University of California at San Francisco. "In order to prevent an escalation in XDR TB we need to ensure adherence to the cornerstones of TB management, which include directly observed therapy, isolation of infectious cases, and contact investigations. We also need to institute routine, rapid, and standardized methods to assess drug susceptibility of TB isolates," she concluded. Infectious Diseases Society of America | |||||||||||||||||||||
|
Related Tuberculosis Current Events and Tuberculosis News Articles Stopping germs from ganging up on humans Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson. First trachea transplant without immunosuppression After 4 years of going from consultation to consultation, Claudia Castillo finally found a solution to her respiratory problems. The young Colombian woman suffered from a cough that took a long time to be diagnosed as tuberculosis. Proteomics Study Yields Clues As To How Tuberculosis Might Be Thwarting The Immune System A link between the immune system and the self-cleaning system by which biological cells rid themselves of obsolete or toxic parts may one day yield new weapons in the fight against tuberculosis and other deadly infectious diseases. XDR-TB: Deadlier and more mysterious than ever New research has found that XDR-TB is increasingly common and more deadly than previously known. Extensively drug-resistant tuberculosis (XDR-TB) is a growing public health threat that is only just beginning to be understood by medical and public health officials. Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Parasites that live inside cells use loophole to thwart immune system St. Jude Children's Research Hospital scientists have discovered a mechanism by which intracellular pathogens can shut down one of the body's key chemical weapons against them: nitric oxide. Persistent bacterial infection exploits killing machinery of immune cells A new study reveals an important and newly discovered pathway used by disease-causing bacteria to evade the host immune system and survive and grow within the very cells meant to destroy them. This discovery may lead to new treatments and vaccines for tuberculosis (TB) and certain other chronic bacterial and parasitic infections. Health Care Barriers for Undocumented Immigrants: Raising Tuberculosis Risk? A new study raises the question, do barriers to health care for undocumented immigrants increase the public health risk of tuberculosis? The study, published in the November 15, 2008 issue of Clinical Infectious Diseases and now available online, suggests that undocumented immigrants with tuberculosis have symptoms longer before seeking care than documented immigrants or U.S.-born patients, resulting in more severe symptoms and more opportunities for transmission. UCLA develops safer, more effective TB vaccine for HIV-positive people UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials. New TB test reveals patients at risk, says study A recently introduced blood test can reveal which patients may develop active tuberculosis (TB) much more precisely than the 100-year old TB skin test, according to a new study published today in the journal Annals of Internal Medicine. More Tuberculosis Current Events and Tuberculosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||